Recently Featured

AstraZeneca’s Emerald Program Advances with Imfinzi and Imjudo in Liver Cancer Treatment

April 11, 2026
Another green light appears increasingly within reach for AstraZeneca’s Emerald program after a combination regimen featuring the company’s immunotherapy duo, Imfinzi and Imjudo, demonstrated a significant progression-free survival benefit in patients with locoregional liver cancer. This development marks a pivotal moment for AstraZeneca as it seeks to solidify its position in the oncology market. The…

Eli Lilly Wins FDA Approval for Weight Loss Pill, Tees Up Novo Rivalry

April 11, 2026
Eli Lilly has secured FDA approval for its weight loss medication, Foundayo, positioning the company for potential blockbuster sales in a rapidly growing market. This approval marks a significant milestone for Lilly as it enters a competitive landscape dominated by established players like Novo Nordisk, which has long been a leader in obesity treatments. The…

Sevabertinib Approved for HER2-Positive Lung Cancer Treatment

April 11, 2026
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for sevabertinib, a novel treatment for adults diagnosed with HER2-positive lung cancer that is either metastatic or unresectable. This decision marks a significant advancement in targeted therapy options for this patient population, which has historically faced limited treatment alternatives. This approval comes in…

Emerging Trends in Pharma Collaboration Highlighted by New Insights

April 11, 2026
Recent discussions among industry leaders emphasize the growing importance of collaboration in the pharmaceutical sector. As companies face increasing regulatory pressures and the need for rapid innovation, the ability to work together effectively has become a critical success factor. This shift is not merely a trend; it reflects a fundamental change in how pharmaceutical firms…

Ongoing Cases